Altogether, these data indicate that high inclusion levels of ECT2-Ex5 are a predictive marker of bad prognosis in breast cancer, specifically in the HR+ERBB2- subtype (as opposed to triple-negative tumors) and in patients that were treated with chemotherapy. This evidence concerns the gene ECT2 and breast cancer.